Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

Diabetes, Obesity & Metabolism
T HaakH-J Woerle

Abstract

To evaluate the efficacy and safety of initial combination therapy with linagliptin plus metformin versus linagliptin or metformin monotherapy in patients with type 2 diabetes. In this 24-week, double-blind, placebo-controlled, Phase III trial, 791 patients were randomized to one of six treatment arms. Two free combination therapy arms received linagliptin 2.5 mg twice daily (bid) + either low (500 mg) or high (1000 mg) dose metformin bid. Four monotherapy arms received linagliptin 5 mg once daily, metformin 500 mg or 1000 mg bid or placebo. Patients with haemoglobin A1c (HbA1c) ≥11.0% were not eligible for randomization and received open-label linagliptin + high-dose metformin. The placebo-corrected mean (95% confidence interval) change in HbA1c from baseline (8.7%) to week 24 was -1.7% (-2.0, -1.4) for linagliptin + high-dose metformin, -1.3% (-1.6, -1.1) for linagliptin + low-dose metformin, -1.2% (-1.5, -0.9) for high-dose metformin, -0.8% (-1.0, -0.5) for low-dose metformin and -0.6 (-0.9, -0.3) for linagliptin (all p < 0.0001). In the open-label arm, the mean change in HbA1c from baseline (11.8%) was -3.7%. Hypoglycaemia occurred at a similar low rate with linagliptin + metformin (1.7%) as with metformin alone (2.4%). Adv...Continue Reading

References

Nov 1, 1996·The Journal of Clinical Endocrinology and Metabolism·K CusiR A DeFronzo
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Sharon H SaydahCatherine C Cowie
Oct 16, 2004·The Journal of Clinical Endocrinology and Metabolism·Ele FerranniniRalph A DeFronzo
Oct 7, 2005·The New England Journal of Medicine·Amir TiroshUNKNOWN Israeli Diabetes Research Group
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
Dec 6, 2007·International Journal of Clinical Practice. Supplement·B J GoldsteinUNKNOWN Global Partnership for Effective Diabetes Management
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Nov 13, 2009·Diabetes Care·Stefano Del PratoRoberto Miccoli
Dec 2, 2009·Expert Opinion on Investigational Drugs·Carolyn F Deacon, Jens J Holst
Jan 21, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stefan BlechKlaus Wagner
May 14, 2010·Postgraduate Medicine·Kannayiram Alagiakrishnan, Laurie Mereu
Jun 12, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·R A DeFronzoM E Wintle
Oct 1, 2010·Diabetes, Obesity & Metabolism·E E WrightR M Cuddihy
Jan 14, 2011·The American Journal of Medicine·Bernard Zinman
Apr 16, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Yehuda HandelsmanUNKNOWN AACE Task Force for Developing Diabetes Comprehensive Care Plan

❮ Previous
Next ❯

Citations

Apr 23, 2013·Advances in Therapy·Andrea D Fass, Jennifer A Gershman
Sep 24, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jaime A Davidson
May 24, 2013·Diabetology & Metabolic Syndrome·Erika Paniago GuedesFelipe Lauand
May 23, 2014·Drug Design, Development and Therapy·John Doupis
Apr 2, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Shikhar AgarwalVenu Menon
Mar 26, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Paul CraddyK Ian Johnson
May 6, 2014·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·M MonamiE Mannucci
Sep 2, 2014·European Journal of Clinical Pharmacology·George Grunberger
Jun 12, 2013·Postgraduate Medicine·George Grunberger
Nov 20, 2015·Expert Opinion on Pharmacotherapy·C TriplittRalph A Defronzo
Feb 5, 2013·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Feb 21, 2013·Expert Opinion on Drug Safety·André J Scheen
Oct 30, 2014·Expert Opinion on Drug Safety·Anthony H Barnett
Mar 17, 2015·Current Medical Research and Opinion·Ronnie Aronson
Mar 19, 2016·International Journal of Cardiology·J KongwatcharapongN Chaiyakunapruk
Aug 26, 2015·International Journal of Clinical Practice·V Woo
Dec 25, 2015·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Abdulrahman S Alanazi
Sep 5, 2015·Pharmaceutical Statistics·Björn HolzhauerGeorgina Bermann
Sep 28, 2012·Diabetes, Obesity & Metabolism·D S H Bell
Nov 5, 2014·International Journal of Clinical Practice·M E RotzT F Thomas
Apr 15, 2016·Science Translational Medicine·Hui WangHongting Zheng
Sep 30, 2015·Diabetes/metabolism Research and Reviews·Wenjia YangLinong Ji

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.